Vimarsana
Biggest News Aggregation in the World

Robert Coffin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Robert Coffin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Robert Coffin Today - Breaking & Trending Today

DW DW News July 13, 2024 - Vimarsana News

DW DW News July 13, 2024

Discussed the coronavirus urge Member States to put solidarity above National Interests as china sees a sharp drop in manufacturing exports how severe is the threat to the Global Economy. And in german sucka battling for a shot at the top dog and glass back both think they can challenge by a new name for the league title saturdays a must win match gives them both a chance to prove it. Im a backer it has welcome to the program tensions are intensifying on graces border with turkey as thousands of migrants seek to enter europe the European Union has told them theyll not be allowed to enter and h...

Leerink Partnrs Weighs in on Replimune Group, Inc.'s Q1 2025 Earnings (NASDAQ:REPL) - Vimarsana News

Leerink Partnrs Weighs in on Replimune Group, Inc.'s Q1 2025 Earnings (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL – Free Report) – Research analysts at Leerink Partnrs dropped their Q1 2025 earnings estimates for shares of Replimune Group in a research report issued on Thursday, May 16th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.85) per share for the quarter, down from their previous […]

Replimune Presents Updated Interim Results from the ARTACUS - Vimarsana News

Replimune Presents Updated Interim Results from the ARTACUS

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients...

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma - Vimarsana News

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

31.07.2023 - Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a ... Seite 1

Replimune Group (NASDAQ:REPL) Shares Gap Up to $23.48 - Vimarsana News

Replimune Group (NASDAQ:REPL) Shares Gap Up to $23.48

Replimune Group, Inc. (NASDAQ:REPL – Get Rating)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $23.48, but opened at $24.60. Replimune Group shares last traded at $24.39, with a volume of 44,521 shares. Wall Street Analysts Forecast Growth A number of research analysts have weighed in […]